HCPCS Service Codes - Medical care

HCPCS Service Code 1 for Medical care.

HCPCS Type of Service (TOS) code is an indicator that the contractor places on Form CMS-1500. The indicator is mainly used for data purposes, however in some instances, it affects payment. All HCPCS codes have a corresponding TOS indicator.

Below are all available HCPCS TOS codes. Find an HCPCS code based on the type of service.

HCPCS Codes for Medical care

  • J9313

    Injection, moxetumomab pasudotox-tdfk, 0.01 mg

  • J9314

    Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg

  • J9315

    Injection, romidepsin, 1 mg

  • J9316

    Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg

  • J9317

    Injection, sacituzumab govitecan-hziy, 2.5 mg

  • J9318

    Injection, romidepsin, non-lyophilized, 0.1 mg

  • J9319

    Injection, romidepsin, lyophilized, 0.1 mg

  • J9320

    Injection, streptozocin, 1 gram

  • J9321

    Injection, epcoritamab-bysp, 0.16 mg

  • J9322

    Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg

  • J9323

    Injection, pemetrexed ditromethamine, 10 mg

  • J9324

    Injection, pemetrexed (pemrydi rtu), 10 mg

  • J9325

    Injection, talimogene laherparepvec, per 1 million plaque forming units

  • J9326

    Injection, telisotuzumab vedotin-tllv, 1 mg

  • J9328

    Injection, temozolomide, 1 mg

  • J9329

    Injection, tislelizumab-jsgr, 1mg

  • J9330

    Injection, temsirolimus, 1 mg

  • J9331

    Injection, sirolimus protein-bound particles, 1 mg

  • J9332

    Injection, efgartigimod alfa-fcab, 2mg

  • J9333

    Injection, rozanolixizumab-noli, 1 mg

  • J9334

    Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc

  • J9340

    Injection, thiotepa, 15 mg

  • J9341

    Injection, thiotepa (tepylute), 1 mg

  • J9342

    Injection, thiotepa, not otherwise specified, 1 mg

  • J9345

    Injection, retifanlimab-dlwr, 1 mg

  • J9347

    Injection, tremelimumab-actl, 1 mg

  • J9348

    Injection, naxitamab-gqgk, 1 mg

  • J9349

    Injection, tafasitamab-cxix, 2 mg

  • J9350

    Injection, mosunetuzumab-axgb, 1 mg

  • J9351

    Injection, topotecan, 0.1 mg

  • J9352

    Injection, trabectedin, 0.1 mg

  • J9353

    Injection, margetuximab-cmkb, 5 mg

  • J9354

    Injection, ado-trastuzumab emtansine, 1 mg

  • J9355

    Injection, trastuzumab, excludes biosimilar, 10 mg

  • J9356

    Injection, trastuzumab, 10 mg and hyaluronidase-oysk

  • J9357

    Injection, valrubicin, intravesical, 200 mg

  • J9358

    Injection, fam-trastuzumab deruxtecan-nxki, 1 mg

  • J9359

    Injection, loncastuximab tesirine-lpyl, 0.075 mg

  • J9360

    Injection, vinblastine sulfate, 1 mg

  • J9361

    Injection, efbemalenograstim alfa-vuxw, 0.5 mg

  • J9370

    Vincristine sulfate, 1 mg

  • J9371

    Injection, vincristine sulfate liposome, 1 mg

  • J9376

    Injection, pozelimab-bbfg, 1 mg

  • J9380

    Injection, teclistamab-cqyv, 0.5 mg

  • J9381

    Injection, teplizumab-mzwv, 5 mcg

  • J9382

    Injection, zenocutuzumab-zbco, 1 mg

  • J9390

    Injection, vinorelbine tartrate, 10 mg

  • J9393

    Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg

  • J9394

    Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg

  • J9395

    Injection, fulvestrant, 25 mg